Dans la même rubrique
-
Partager cette page
Karim Amighi
Département de Pharmacothérapie et de pharmacie galénique - Unité de pharmacie galénique et de biopharmacie
ContactRESEARCH ACTIVITIES
His research interests are in the field of the formulation and in vitro/in vivo evaluation of advanced drug delivery systems for oral, parenteral, pulmonary, and nasal routes of administration. His research programme on lung drug delivery ranges from in vitro evaluation, through to evaluation of new excipients and/or devices, particle engineering and production using novel processes, and aerosol formulation, to in vivo scintigraphy imaging of lung deposition, local and systemic drug bioavailability, and clinical outcomes.
He has been responsible for more than 50 competitive research projects financed by regional funds or by national and international pharmaceuticals companies (budget > 15M €). He has initiated recently the launch of a new spin-off company (InhaTarget Therapeutics) in lung cancer targeted therapy field, and the marketing of a new inhalation product for the treatment of COPD.
Selected publications
En attente des données.
Rafraîchir.
Career
- (2019-) Cofounder and member of the Board of InhaTarget Therapeutics
- (2015-) Full Professor at the Faculty of Pharmacy (ULB)
- (2011-2015) Dean of the Faculty of Pharmacy (ULB)
- (2009-2015) Professor at the Faculty of Pharmacy (ULB)
- (2007-2011) Vice-Dean of the Faculty of Pharmacy (ULB)
- (2001-) Director of the laboratory of Pharmaceutics and Biopharmaceutics, Faculty of Pharmacy (ULB)
- (1997-2001) Associate Professor at Faculty of Pharmacy (ULB)
- (1988-1997) Research Assistant, Faculty of Pharmacy (ULB)